The Technical AnalystExchange: OTC Sector: Healthcare Industry: Biotechnology
Organicell Regenerative Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.27% $2.74
America/New_York / 4 mar 2024 @ 15:14
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 19.97 mill |
| EPS: | -1.750 |
| P/E: | -1.567 |
| Earnings Date: | Apr 29, 2023 |
| SharesOutstanding: | 7.28 mill |
| Avg Daily Volume: | 0.0047 mill |
| RATING 2024-03-04 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Sell | |
| DE: | Strong Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.567 | sector: PE 29.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.01x |
| Company: PE -1.567 | industry: PE 136.10 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 1.353 - 2.19 ( +/- 23.56%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-06-29 | Leider Harry L. | Buy | 500 000 | Common Stock |
| 2023-06-28 | Leider Harry L. | Buy | 549 450 | Common Stock |
| 2023-12-19 | Leider Harry L. | Sell | 5 248 | Common Stock |
| 2023-07-07 | Skycrest Holdings, Llc | Buy | 320 710 | Common Stock |
| 2023-06-29 | Skycrest Holdings, Llc | Buy | 200 000 | Common Stock |
| INSIDER POWER |
|---|
| -77.67 |
| Last 93 transactions |
| Buy: 116 969 610 | Sell: 385 387 546 |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $2.74 (-0.27% ) |
| Volume | 0.0047 mill |
| Avg. Vol. | 0.0047 mill |
| % of Avg. Vol | 100.40 % |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For OCEL
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
OCEL
Organicell Regenerative Medicine, Inc., a clinical-stage biopharmaceutical company, focuses on the development of biological therapeutics for the treatment of degenerative diseases. Its leading product candidate is Zofin, an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs without the addition or combination of any other substance or diluent, which is in Phase I/II clinical trial to treat COVID-19. The company also provides independent education, advertising, and marketing services to medical and other healthcare, anti-aging, and regenerative service providers. It has a research and development agreement with the Centers for Disease Control and Prevention to determine the anti-inflammatory and anti-infective effectiveness of Zofin in experimental models of influenza infection; and an agreement with Oklahoma State University to evaluate Zofin for the treatment of respiratory diseases caused by virus infections of pandemic potential. The company was formerly known as Biotech Products Services and Research, Inc. and changed its name to Organicell Regenerative Medicine, Inc. in June 2018. Organicell Regenerative Medicine, Inc. was incorporated in 2011 and is headquartered in Miami, Florida.